GlaxoSmithKline to cease providing corporate political contributions

GlaxoSmithKlineGlaxoSmithKline has announced a new global policy to voluntarily stop all corporate political contributions. In the past, GSK - in common with many companies and in full compliance with local laws - has made a number of corporate contributions in countries such as the US and Canada. GSK's new policy will ensure that no such contributions will be made in the future.

"We continue to believe that it is important for GSK to be engaged in policy debates and the political process. However, we need to ensure that there is no implication whatsoever that corporate political contributions provide us with any special privileges. We do not believe they have, and in the few countries we have given contributions we have done so in full compliance of the law. As part of our overall drive to improve transparency in terms of our interactions with governments, political leaders and candidates for public office, we believe that stopping corporate political contributions is the right thing to do. Our focus is, as it always has been, on helping governments by providing them with evidence that our medicines and vaccines provide a strong value proposition," said Andrew Witty, CEO, GlaxoSmithKline.

In the US, the company will continue to support a voluntary and independent Political Action Committee (PAC) to facilitate political contributions by eligible GSK employees.

About GlaxoSmithKline
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

Most Popular Now

Pfizer announces positive top-line results from Ph…

Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational ...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

Enzyme that protects against viruses could fuel ca…

An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells, according to a ...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...